Reports

European biosimilars market set to grow gradually

A new report from Frost & Sullivan (F&S) has claimed that despite the initial regulatory hiccups, the number of biosimilars in the European market is set to increase gradually. It notes that patent expiries of key biopharmaceuticals have opened up numerous lucrative market opportunities, while driving the development of biosimilars. In addition, payers' perception of biosimilars, as viable alternatives to originator drugs due to their safety, efficacy and affordability, will further bolster market prospects.